The global glucose tracking app market is projected to grow from USD 5.00 billion in 2025 to USD 12.00 billion by 2033, expanding at a CAGR of 15.0 percent, according to Verified Market Research.
The forecast reflects a broader shift in diabetes care from episodic clinical intervention toward continuous, data-driven disease management. As patients, caregivers and clinicians seek better visibility into glucose patterns, mobile applications are moving beyond simple logging tools into connected platforms that support adherence, pattern recognition and care coordination.
Glucose tracking apps are designed to capture, interpret, monitor and communicate glucose-related information across diabetes care workflows. Core functions include recording blood glucose readings, visualising trends, supporting adherence routines, issuing alerts, providing education and enabling structured decision support. Predictive analytics and AI-based apps are emerging as a higher-growth segment as the market shifts toward proactive guidance.
The unmet need is significant. Rising diabetes prevalence continues to expand the addressable user base, while real-world care increasingly requires longitudinal monitoring rather than isolated glucose readings. For clinicians, longer-term data can support trend interpretation and intervention timing. For patients and caregivers, mobile tools can reduce friction in daily self-management and improve visibility between clinical encounters.
North America currently leads the global glucose tracking app market with approximately 38 percent market share, supported by high diabetes prevalence, digital health adoption, connected healthcare ecosystems and strong technology infrastructure. Asia Pacific is also emerging as a major growth region, driven by smartphone penetration, growing diabetes populations and telehealth expansion.
The competitive landscape remains moderately fragmented, with key participants including Roche, Abbott Laboratories, Dexcom, Medtronic, Tidepool, Glooko, DarioHealth, One Drop, mySugr, Ascensia Diabetes Care, HealthifyMe and Ultrahuman. Competition is increasingly centred on interoperability, regulatory reliability, user retention and AI-powered insights.
However, adoption is not without barriers. Regulatory requirements, data privacy expectations, interoperability demands and the cost of maintaining clinically reliable digital platforms may constrain sustainable growth. Healthcare organisations will also need systems that fit into clinical workflows, support documentation and provide data that clinicians can trust.
The market’s next phase will likely be shaped by applications that can move from passive tracking to integrated decision-support environments. As diabetes management becomes more connected, value creation will depend on data continuity, workflow compatibility, platform integration and the ability to support more consistent patient engagement.
